The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer
Serum CA 125 levels were obtained from 55 women with epithelial ovarian cancer before a second-look surgical procedure and serially thereafter. All patients were clinically and radiographically free of tumor at the time of the second-look operation and were followed to clinical recurrence. Median fo...
Gespeichert in:
| Veröffentlicht in: | American journal of obstetrics and gynecology 1986-07, Vol.155 (1), p.56-60 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 60 |
|---|---|
| container_issue | 1 |
| container_start_page | 56 |
| container_title | American journal of obstetrics and gynecology |
| container_volume | 155 |
| creator | Niloff, Jonathan M. Knapp, Robert C. Lavin, Philip T. Malkasian, George D. Berek, Jonathan S. Mortel, Rodrigue Whitney, Charles Zurawski, Vincent R. Bast, Robert C. |
| description | Serum CA 125 levels were obtained from 55 women with epithelial ovarian cancer before a second-look surgical procedure and serially thereafter. All patients were clinically and radiographically free of tumor at the time of the second-look operation and were followed to clinical recurrence. Median follow-up was 12 months. CA 125 levels obtained at the second-look operation had a sensitivity and specificity for predicting clinical recurrence of 94% and 88%, respectively. Patients with an elevated CA 125 level (≥35 U/ml) had a 60% chance of clinical recurrence within 4 months, while patients with levels |
| doi_str_mv | 10.1016/0002-9378(86)90077-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76932282</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0002937886900773</els_id><sourcerecordid>76932282</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-dd4261478c67d504471e51923133a55eb3ee861c6cacc1e4aae33c2f091eefce3</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMo6_rxDxRyENFDNR9tkl4EWfwCwYPrOcTpFCPddk3ahf33pu6yRy8ThveZYfIQcsbZDWdc3TLGRFZKba6Mui4Z0zqTe2TKWakzZZTZJ9MdckiOYvweW1GKCZnIXDGZ8yl5n38hnd1TLgrqYnTrVKmjy4CVh74LtKspNL714BoaEIYQsAWkvqW49P0XNj4F3coF71oKLmXhhBzUrol4un2Pycfjw3z2nL2-Pb3M7l8zkEb1WVXlQvFcG1C6Kliea44FL4XkUrqiwE-JaBQHBQ6AY-4cSgmiZiVHrAHlMbnc7F2G7mfA2NuFj4BN41rshmi1KqUQRiQw34AQuhgD1nYZ_MKFteXMji7taMaOoqxR9s-llWnsfLt_-FxgtRvaykv5xTZ3MempQ_q9jzvMMC51USTsboNhcrHyGGwEP0qsfBLa26rz_9_xC9zojos</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76932282</pqid></control><display><type>article</type><title>The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Niloff, Jonathan M. ; Knapp, Robert C. ; Lavin, Philip T. ; Malkasian, George D. ; Berek, Jonathan S. ; Mortel, Rodrigue ; Whitney, Charles ; Zurawski, Vincent R. ; Bast, Robert C.</creator><creatorcontrib>Niloff, Jonathan M. ; Knapp, Robert C. ; Lavin, Philip T. ; Malkasian, George D. ; Berek, Jonathan S. ; Mortel, Rodrigue ; Whitney, Charles ; Zurawski, Vincent R. ; Bast, Robert C.</creatorcontrib><description>Serum CA 125 levels were obtained from 55 women with epithelial ovarian cancer before a second-look surgical procedure and serially thereafter. All patients were clinically and radiographically free of tumor at the time of the second-look operation and were followed to clinical recurrence. Median follow-up was 12 months. CA 125 levels obtained at the second-look operation had a sensitivity and specificity for predicting clinical recurrence of 94% and 88%, respectively. Patients with an elevated CA 125 level (≥35 U/ml) had a 60% chance of clinical recurrence within 4 months, while patients with levels <35 U/ml had a 5% chance of clinical recurrence over the same time period. Serial CA 125 levels obtained after second-look operations were strong predictors of clinical outcome, and distinctly different monitoring profiles were observed among those patients remaining clinically free of tumor and those suffering clinical recurrence. The CA 125 assay became elevated (≥35 U/ml) before clinical recurrence in 94% of 35 cases with a median lead time of 3 months. The CA 125 assay identifies patients destined to suffer a clinical recurrence and provides a warning measurable in months. This may have important implications for therapy.</description><identifier>ISSN: 0002-9378</identifier><identifier>EISSN: 1097-6868</identifier><identifier>DOI: 10.1016/0002-9378(86)90077-3</identifier><identifier>PMID: 3460341</identifier><identifier>CODEN: AJOGAH</identifier><language>eng</language><publisher>Philadelphia, PA: Elsevier Inc</publisher><subject>Adult ; Aged ; Antigens, Neoplasm - analysis ; Antigens, Tumor-Associated, Carbohydrate ; Biological and medical sciences ; CA 125 radiometric assay ; Carcinoma - diagnosis ; Carcinoma - surgery ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Humans ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local - diagnosis ; ovarian cancer ; Ovarian Neoplasms - diagnosis ; Ovarian Neoplasms - surgery ; Prognosis ; Reoperation ; second-look surgical procedure ; Time Factors ; Tumors</subject><ispartof>American journal of obstetrics and gynecology, 1986-07, Vol.155 (1), p.56-60</ispartof><rights>1986</rights><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-dd4261478c67d504471e51923133a55eb3ee861c6cacc1e4aae33c2f091eefce3</citedby><cites>FETCH-LOGICAL-c386t-dd4261478c67d504471e51923133a55eb3ee861c6cacc1e4aae33c2f091eefce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0002-9378(86)90077-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8013755$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3460341$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niloff, Jonathan M.</creatorcontrib><creatorcontrib>Knapp, Robert C.</creatorcontrib><creatorcontrib>Lavin, Philip T.</creatorcontrib><creatorcontrib>Malkasian, George D.</creatorcontrib><creatorcontrib>Berek, Jonathan S.</creatorcontrib><creatorcontrib>Mortel, Rodrigue</creatorcontrib><creatorcontrib>Whitney, Charles</creatorcontrib><creatorcontrib>Zurawski, Vincent R.</creatorcontrib><creatorcontrib>Bast, Robert C.</creatorcontrib><title>The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer</title><title>American journal of obstetrics and gynecology</title><addtitle>Am J Obstet Gynecol</addtitle><description>Serum CA 125 levels were obtained from 55 women with epithelial ovarian cancer before a second-look surgical procedure and serially thereafter. All patients were clinically and radiographically free of tumor at the time of the second-look operation and were followed to clinical recurrence. Median follow-up was 12 months. CA 125 levels obtained at the second-look operation had a sensitivity and specificity for predicting clinical recurrence of 94% and 88%, respectively. Patients with an elevated CA 125 level (≥35 U/ml) had a 60% chance of clinical recurrence within 4 months, while patients with levels <35 U/ml had a 5% chance of clinical recurrence over the same time period. Serial CA 125 levels obtained after second-look operations were strong predictors of clinical outcome, and distinctly different monitoring profiles were observed among those patients remaining clinically free of tumor and those suffering clinical recurrence. The CA 125 assay became elevated (≥35 U/ml) before clinical recurrence in 94% of 35 cases with a median lead time of 3 months. The CA 125 assay identifies patients destined to suffer a clinical recurrence and provides a warning measurable in months. This may have important implications for therapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Antigens, Neoplasm - analysis</subject><subject>Antigens, Tumor-Associated, Carbohydrate</subject><subject>Biological and medical sciences</subject><subject>CA 125 radiometric assay</subject><subject>Carcinoma - diagnosis</subject><subject>Carcinoma - surgery</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>ovarian cancer</subject><subject>Ovarian Neoplasms - diagnosis</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Prognosis</subject><subject>Reoperation</subject><subject>second-look surgical procedure</subject><subject>Time Factors</subject><subject>Tumors</subject><issn>0002-9378</issn><issn>1097-6868</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMo6_rxDxRyENFDNR9tkl4EWfwCwYPrOcTpFCPddk3ahf33pu6yRy8ThveZYfIQcsbZDWdc3TLGRFZKba6Mui4Z0zqTe2TKWakzZZTZJ9MdckiOYvweW1GKCZnIXDGZ8yl5n38hnd1TLgrqYnTrVKmjy4CVh74LtKspNL714BoaEIYQsAWkvqW49P0XNj4F3coF71oKLmXhhBzUrol4un2Pycfjw3z2nL2-Pb3M7l8zkEb1WVXlQvFcG1C6Kliea44FL4XkUrqiwE-JaBQHBQ6AY-4cSgmiZiVHrAHlMbnc7F2G7mfA2NuFj4BN41rshmi1KqUQRiQw34AQuhgD1nYZ_MKFteXMji7taMaOoqxR9s-llWnsfLt_-FxgtRvaykv5xTZ3MempQ_q9jzvMMC51USTsboNhcrHyGGwEP0qsfBLa26rz_9_xC9zojos</recordid><startdate>19860701</startdate><enddate>19860701</enddate><creator>Niloff, Jonathan M.</creator><creator>Knapp, Robert C.</creator><creator>Lavin, Philip T.</creator><creator>Malkasian, George D.</creator><creator>Berek, Jonathan S.</creator><creator>Mortel, Rodrigue</creator><creator>Whitney, Charles</creator><creator>Zurawski, Vincent R.</creator><creator>Bast, Robert C.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19860701</creationdate><title>The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer</title><author>Niloff, Jonathan M. ; Knapp, Robert C. ; Lavin, Philip T. ; Malkasian, George D. ; Berek, Jonathan S. ; Mortel, Rodrigue ; Whitney, Charles ; Zurawski, Vincent R. ; Bast, Robert C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-dd4261478c67d504471e51923133a55eb3ee861c6cacc1e4aae33c2f091eefce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antigens, Neoplasm - analysis</topic><topic>Antigens, Tumor-Associated, Carbohydrate</topic><topic>Biological and medical sciences</topic><topic>CA 125 radiometric assay</topic><topic>Carcinoma - diagnosis</topic><topic>Carcinoma - surgery</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>ovarian cancer</topic><topic>Ovarian Neoplasms - diagnosis</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Prognosis</topic><topic>Reoperation</topic><topic>second-look surgical procedure</topic><topic>Time Factors</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niloff, Jonathan M.</creatorcontrib><creatorcontrib>Knapp, Robert C.</creatorcontrib><creatorcontrib>Lavin, Philip T.</creatorcontrib><creatorcontrib>Malkasian, George D.</creatorcontrib><creatorcontrib>Berek, Jonathan S.</creatorcontrib><creatorcontrib>Mortel, Rodrigue</creatorcontrib><creatorcontrib>Whitney, Charles</creatorcontrib><creatorcontrib>Zurawski, Vincent R.</creatorcontrib><creatorcontrib>Bast, Robert C.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of obstetrics and gynecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niloff, Jonathan M.</au><au>Knapp, Robert C.</au><au>Lavin, Philip T.</au><au>Malkasian, George D.</au><au>Berek, Jonathan S.</au><au>Mortel, Rodrigue</au><au>Whitney, Charles</au><au>Zurawski, Vincent R.</au><au>Bast, Robert C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer</atitle><jtitle>American journal of obstetrics and gynecology</jtitle><addtitle>Am J Obstet Gynecol</addtitle><date>1986-07-01</date><risdate>1986</risdate><volume>155</volume><issue>1</issue><spage>56</spage><epage>60</epage><pages>56-60</pages><issn>0002-9378</issn><eissn>1097-6868</eissn><coden>AJOGAH</coden><abstract>Serum CA 125 levels were obtained from 55 women with epithelial ovarian cancer before a second-look surgical procedure and serially thereafter. All patients were clinically and radiographically free of tumor at the time of the second-look operation and were followed to clinical recurrence. Median follow-up was 12 months. CA 125 levels obtained at the second-look operation had a sensitivity and specificity for predicting clinical recurrence of 94% and 88%, respectively. Patients with an elevated CA 125 level (≥35 U/ml) had a 60% chance of clinical recurrence within 4 months, while patients with levels <35 U/ml had a 5% chance of clinical recurrence over the same time period. Serial CA 125 levels obtained after second-look operations were strong predictors of clinical outcome, and distinctly different monitoring profiles were observed among those patients remaining clinically free of tumor and those suffering clinical recurrence. The CA 125 assay became elevated (≥35 U/ml) before clinical recurrence in 94% of 35 cases with a median lead time of 3 months. The CA 125 assay identifies patients destined to suffer a clinical recurrence and provides a warning measurable in months. This may have important implications for therapy.</abstract><cop>Philadelphia, PA</cop><pub>Elsevier Inc</pub><pmid>3460341</pmid><doi>10.1016/0002-9378(86)90077-3</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9378 |
| ispartof | American journal of obstetrics and gynecology, 1986-07, Vol.155 (1), p.56-60 |
| issn | 0002-9378 1097-6868 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76932282 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Aged Antigens, Neoplasm - analysis Antigens, Tumor-Associated, Carbohydrate Biological and medical sciences CA 125 radiometric assay Carcinoma - diagnosis Carcinoma - surgery Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Medical sciences Middle Aged Neoplasm Recurrence, Local - diagnosis ovarian cancer Ovarian Neoplasms - diagnosis Ovarian Neoplasms - surgery Prognosis Reoperation second-look surgical procedure Time Factors Tumors |
| title | The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A30%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20CA%20125%20assay%20as%20a%20predictor%20of%20clinical%20recurrence%20in%20epithelial%20ovarian%20cancer&rft.jtitle=American%20journal%20of%20obstetrics%20and%20gynecology&rft.au=Niloff,%20Jonathan%20M.&rft.date=1986-07-01&rft.volume=155&rft.issue=1&rft.spage=56&rft.epage=60&rft.pages=56-60&rft.issn=0002-9378&rft.eissn=1097-6868&rft.coden=AJOGAH&rft_id=info:doi/10.1016/0002-9378(86)90077-3&rft_dat=%3Cproquest_cross%3E76932282%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76932282&rft_id=info:pmid/3460341&rft_els_id=0002937886900773&rfr_iscdi=true |